Spelling suggestions: "subject:"achronic lives disease"" "subject:"achronic river disease""
1 |
The epidemiology of chronic liver disease in older people with type 2 diabetes mellitus : the Edinburgh Type 2 Diabetes StudyMorling, Joanne Rebecca January 2015 (has links)
Increasingly chronic liver disease is being acknowledged as a complication of type 2 diabetes, in particular non-alcoholic fatty liver and non-alcoholic fatty liver disease. Rates of non-alcoholic fatty liver are higher in people with type 2 diabetes than in the general population, with prevalence rates believed to be between 40-70%. Given the aging Scottish population and the obesity driven diabetes epidemic, the problem of chronic liver disease is likely to increase. Despite this there has been little investigation into the natural history of nonalcoholic fatty liver disease and the risks of clinically significant chronic liver disease in community based cohorts because diagnosis has been heavily reliant on liver biopsy. The use of liver biopsy is limited in both research and clinical practice due to its associated high mortality (1/1000) and morbidity and also due to practical limitations (sampling variability, semi-quantitative scoring systems). As a result the use of non-invasive markers of liver injury (non-specific liver injury, steatosis, steatohepatitis, liver fibrosis and surrogates of advanced portal hypertension) are rising, in the diagnosis of chronic liver disease, however, their utility in both community cohorts and patients with type 2 diabetes has not been widely studied. The aims of the studies presented in the thesis, using the Edinburgh Type 2 Diabetes Study, were: (i) to describe the distributions of a range of non-invasive markers of steatohepatitis and liver fibrosis in older people with type 2 diabetes, their relationship with metabolic and liver disease risk factors, and to compare the agreement of different non-invasive markers of hepatic fibrosis; (ii) to determine the frequency (prevalence and incidence) of and risk factors for clinically significant chronic liver disease in people with type 2 diabetes; and (iii) to determine the importance of chronic liver disease as a risk factor (or risk marker) for cardiovascular mortality or morbidity in type 2 diabetes. Prior to undertaking this work I undertook a detailed systematic review of the literature relating to the use of non-invasive markers of hepatic fibrosis to inform the choice of markers used in the study. Examination of a wide range of potential markers of steatohepatitis and liver fibrosis found varied relationships with diabetes history. Most commonly, elevated markers of steatohepatitis and liver fibrosis were associated with older age and higher body fat measures. However, most of these relationships between liver markers and body fat measures lost statistical significance when limiting the population to only those with hepatic steatosis and/or non-alcoholic fatty liver disease. There were marked differences in the associations between different liver fibrosis markers and potential diabetes and metabolic risk factors, suggesting that these markers are not actually measuring the same underlying “fibrosis” condition. There was poor correlation between the five markers of liver fibrosis studied. Using the top vigintile (5%) of each marker resulted in excellent agreement on the absence of advanced liver disease but poor agreement on the presence of advanced liver disease. The prevalence of clinically significant CLD (defined as cirrhosis, HCC or gastrooesophageal varices) was 2.2% - 0.9% diagnosed prior to enrolment with an additional 1.4% identified by study investigations. Over nearly 6 years of follow-up, only 1.4% of the cohort developed incident clinically significant CLD. Higher levels of systemic inflammation, steatohepatitis and hepatic fibrosis markers were associated with both unknown prevalent and incident clinically significant chronic liver disease. Less than half of participants developing incident significant disease were identified as high risk by the study investigations. Abnormal liver enzymes were statistically significantly associated with incident cases, however the presence of hepatic steatosis was not. There were 372/1033 (36.0%) patients with prevalent CVD and 319 (30.9%) with prevalent CAD at baseline. After mean follow-up of 4.4 years there were 44/663 incident CVD events, including 27 CAD events. There were 30/82 CVD related deaths. However, risk of dying from or developing CVD was no higher in subjects with steatosis than in those without. There was also no statistically significant relationship between CVD and steatohepatitis or liver fibrosis. The only statistically significant relationship between CVD and any liver markers was with GGT (prevalent CVD, OR 1.28, p=0.007; incident CAD, OR 2.35, p=0.042), suggesting that in our study population, CLD may have little effect on the development of, or mortality from, CVD. In conclusion, the potential for using non-invasive biomarkers to diagnose clinically significant chronic liver disease in type 2 diabetes remains limited, however chronic liver disease is a significant problem in older people with type 2 diabetes and is frequently undiagnosed.
|
2 |
Comparison of Outcomes of Patients With Versus Without Chronic Liver Disease Undergoing Percutaneous Coronary InterventionIstanbuly, Sedralmontaha, Matetic, Andrija, Mohamed, Mohamed O., Panaich, Sidakpal, Velagapudi, Poonam, Elgendy, Islam Y., Paul, Timir K., Alkhouli, Mohamad, Mamas, Mamas A. 01 October 2021 (has links)
There are limited data on the outcomes of chronic liver disease (CLD) patients admitted for percutaneous coronary intervention (PCI). All PCI hospitalizations from the Nationwide Inpatient Sample (2004 to 2015) were analyzed and stratified by the presence, cause and severity of CLD, as well as the indication for PCI. Multivariable logistic regression analysis was performed to determine the adjusted odds ratios (aOR) of in-hospital adverse outcomes in patients with CLD compared with those without CLD. Among 7,296,679 PCI admissions, 54,368 (0.7%) had a CLD diagnosis. Among patients with CLD, 36,853 (67.8%) had severe CLD. Patients with CLD had higher likelihood of adverse outcomes including major adverse cardiovascular and cerebrovascular events (MACCE) (aOR 1.25, 95%CI 1.20 to 1.30), mortality (aOR 1.43, 95%CI 1.35 to 1.51), major bleeding (aOR 2.22, 95%CI 2.12 to 2.32). When accounting for severity, only severe CLD subgroup was more likely to have MACCE and all-cause mortality compared to no-CLD patients (p <0.001). Among CLD etiologic subgroups, those with ‘alcohol-related liver disease’ and ‘other CLD’ were consistently more likely to develop MACCE, all-cause mortality and major bleeding in comparison to no-CLD patients, while ‘chronic viral hepatitis’ subgroup had only increased odds of major bleeding (p <0.001). In conclusion, CLD patients admitted for PCI are more likely to have worse in-hospital outcomes, particularly in the severe CLD subgroup and ‘alcohol-related liver disease’ and ‘other CLD’ etiologic subgroups.
|
3 |
Trends, Management and Outcomes of Acute Myocardial Infarction in Chronic Liver DiseaseMatetic, Andrija, Contractor, Tahmeed, Mohamed, Mohamed O., Bhardwaj, Rahul, Aneja, Ashish, Myint, Phyo K., Rakoski, Mina O., Zieroth, Shelley, Paul, Timir K., Mamas, Mamas A. 01 April 2021 (has links)
Aims: There are limited data on the management and outcomes of chronic liver disease (CLD) patients presenting with acute myocardial infarction (AMI), particularly according to the subtype of CLD. Methods: Using the Nationwide Inpatient Sample (2004-2015), we examined outcomes of AMI patients stratified by severity and sub-types of CLD. Multivariable logistic regression was performed to assess the adjusted odds ratios (aOR) of receipt of invasive management and adverse outcomes in CLD groups compared with no-CLD. Results: Of 7 024 723 AMI admissions, 54 283 (0.8%) had a CLD diagnosis. CLD patients were less likely to undergo coronary angiography (CA) and percutaneous coronary intervention (PCI) (aOR 0.62, 95%CI 0.60-0.63 and 0.59, 95%CI 0.58-0.60, respectively), and had increased odds of adverse outcomes including major adverse cardiovascular and cerebrovascular events (1.19, 95%CI 1.15-1.23), mortality (1.30, 95%CI 1.25-1.34) and major bleeding (1.74, 95%CI 1.67-1.81). In comparison to the non-severe CLD sub-groups, patients with all forms of severe CLD had the lower utilization of CA and PCI (P <.05). Among severe CLD patients, those with alcohol-related liver disease (ALD) had the lowest utilization of CA and PCI; patients with ALD and other CLD (OCLD) had more adverse outcomes than the viral hepatitis sub-group (P <.05). Conclusions: CLD patients presenting with AMI are less likely to receive invasive management and are associated with worse clinical outcomes. Further differences are observed depending on the type as well as severity of CLD, with the worst management and clinical outcomes observed in those with severe ALD and OCLD.
|
4 |
Trends, Management and Outcomes of Acute Myocardial Infarction in Chronic Liver DiseaseMatetic, Andrija, Contractor, Tahmeed, Mohamed, Mohamed O., Bhardwaj, Rahul, Aneja, Ashish, Myint, Phyo K., Rakoski, Mina O., Zieroth, Shelley, Paul, Timir K., Mamas, Mamas A. 01 January 2020 (has links)
Aims: There are limited data on the management and outcomes of chronic liver disease (CLD) patients presenting with acute myocardial infarction (AMI), particularly according to the subtype of CLD. Methods: Using the Nationwide Inpatient Sample (2004-2015), we examined outcomes of AMI patients stratified by severity and sub-types of CLD. Multivariable logistic regression was performed to assess the adjusted odds ratios (aOR) of receipt of invasive management and adverse outcomes in CLD groups compared with no-CLD. Results: Of 7 024 723 AMI admissions, 54 283 (0.8%) had a CLD diagnosis. CLD patients were less likely to undergo coronary angiography (CA) and percutaneous coronary intervention (PCI) (aOR 0.62, 95%CI 0.60-0.63 and 0.59, 95%CI 0.58-0.60, respectively), and had increased odds of adverse outcomes including major adverse cardiovascular and cerebrovascular events (1.19, 95%CI 1.15-1.23), mortality (1.30, 95%CI 1.25-1.34) and major bleeding (1.74, 95%CI 1.67-1.81). In comparison to the non-severe CLD sub-groups, patients with all forms of severe CLD had the lower utilization of CA and PCI (P <.05). Among severe CLD patients, those with alcohol-related liver disease (ALD) had the lowest utilization of CA and PCI; patients with ALD and other CLD (OCLD) had more adverse outcomes than the viral hepatitis sub-group (P <.05). Conclusions: CLD patients presenting with AMI are less likely to receive invasive management and are associated with worse clinical outcomes. Further differences are observed depending on the type as well as severity of CLD, with the worst management and clinical outcomes observed in those with severe ALD and OCLD.
|
5 |
Chronic Liver Disease and the Risk of Osteoporotic Fractures: A Meta-AnalysisHidalgo, Diego F., Boonpheng, Boonphiphop, Sikandar, Sehrish, Nasr, Lubna, Hidalgo, Jessica 16 September 2020 (has links)
Introduction Chronic liver disease (CLD) causes more than 1 million deaths every year and remains a pandemic in the last decade affecting more than 600,000 patients in the United States. Previous studies found patients with CLD had increased risk of osteoporosis, so fractures were inferred to be complications of this condition. The aim of this meta-analysis is to summarize the best evidence that correlates CLD patients and the risk to develop osteoporotic fractures versus control patients without CLD. Methods A review of the literature using MEDLINE and EMBASE database was performed during December 2017. We included cross-sectional and cohort studies that reported relative risks (RR), odds ratios (OR) and hazard ratios (HR) comparing the risk of developing osteoporotic fractures among patients with CLD versus patients without CLD. Pooled OR and 95% confidence interval (CI) were calculated using generic inverse- variance method. The Newcastle-Ottawa scale was used to determine the quality of the studies. Effect estimates from the individual study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird. Results After the review of the literature, seven studies fulfilled the eligibility criteria established during the analysis. Significant association was found between CLD and osteoporotic fractures with a pooled OR of 2.13 (95% CI, 1.79 - 2.52). High heterogeneity among the studies was found (I2=88.5). No publication bias was found using Egger regression test (p=0.44). Conclusion We found a significant association between CLD and the risk of developing osteoporotic fractures. The calculated risk was 2.13 times higher for patients with CLD when compared with controls. The results showed high heterogeneity but no publication bias. More prospective studies are needed to fully understand the mechanisms involved in loss of bone density and osteoporotic fractures in order to improve the morbidity associated with this disease.
|
6 |
Avaliação nutricional do paciente com doença hepática crônica / Nutritional status in patients with chronic liver diseaseTatiana Mazza de Castro 07 January 2009 (has links)
Além de muito freqüente, a desnutrição associa-se a morbi/mortalidade em pacientes com doenças hepáticas crônicas. A avaliação do estado nutricional em hepatopatas é difícil pela sobrecarga hídrica e pela alteração na síntese protéica, fatores que alteram os parâmetros tradicionalmente usados na avaliação nutricional. Os objetivos são:a)avaliar o estado nutricional, através da AGS, antropometria, do escore
de Mendenhall e da combinação de todos os instrumentos, em pacientes com doença hepática crônica; b)correlacionar o estado nutricional com a gravidade de doença hepática crônica; c)determinar a contribuição da dinamometria do aperto de mão para a avaliação do estado nutricional. Foram incluídos 305 pacientes portadores de doenças hepáticas crônicas, com idade de 18-80 anos, atendidos no ambulatório de doenças hepatobiliares do Hospital Universitátio Pedro Ernesto. A gravidade da doença hepática foi avaliada pela classificação de Child-Pugh e escore de Meld. Foram aferidos parâmetros antropométricos (peso, altura, índice de massa corporal, prega cutânea triciptal, circunferência do braço, circunferência muscular do braço), parâmetros bioquímicos (albumina e contagem total de linfócitos), Avaliação Global Subjetiva,
escore de Mendenhall e força do aperto de mão pela dinamometria. Os valores da porcentagem de adequação dos parâmetros foram utilizados para a classificação da desnutrição. Consideramos todos os pacientes com porcentagens de adequação abaixo de 90% como desnutridos. Foi criado o escore risco de desnutrição que se caracterizou pela alteração em qualquer um dos parâmetros da avaliação nutricional. Cerca de 53% dos pacientes eram do sexo masculino, 43% portadores de cirrose hepática, 80% com etiologia viral e média de idade de 54 12 anos. Houve relação estatisticamente significativa entre a classificação funcional da doença hepática e a AGS, o escore de Mendenhall e o de risco de desnutrição. A avaliação isolada da antropometria não se correlacionou com a classificação funcional. Segundo a AGS, a prevalência de
desnutrição foi de 10% na hepatopatia não cirrótica, 16% na cirrose compensada e 94% na cirrose descompensada. Segundo o escore de Mendenhall, as cifras foram de 31%, 38% e 56%, respectivamente. Segundo o novo escore, as cifras foram de 52%, 60% e 96%, respectivamente. Embora tenha havido uma redução estatisticamente significativa da força muscular com o agravamento do estado nutricional, não foi possível estabelecer um ponto de corte para os valores da dinamometria. A análise do
desempenho do percentual de adequação da força muscular como critério diagnóstico de pacientes sob risco de desnutrição revelou provavelmente 56% de falso-positivos e 24% de falso-negativos. A grande variação na prevalência de desnutrição em pacientes com doença hepática depende do instrumento de avaliação nutricional usado e da classificação funcional da doença hepática. Não surpreendentemente, os escores
combinados detectaram as maiores taxas de prevalência de desnutrição. Houve associação significativa entre o estado nutricional e a gravidade da doença hepática. O aumento das taxas de prevalência de desnutrição trazido pela dinamometria ocorreu às custas de resultados falso-positivos. / Malnutrition is often present and under diagnosed in patients with chronic liver diseases. Many of the traditional methods used to evaluate nutritional status may be altered by edema, ascites, and protein deficit caused by liver disfunction. To compare different methods to assess nutritional status; to correlate nutritional status with severity of liver dysfunction, and to determine the role of handgrip strength to nutritional
assessment in patients with chronic liver disease. This prospective, cross-sectional study evaluated 305 consecutive outpatients adults with chronic liver disease. The severity of liver dysfunction was assessed by Child`s classification and Meld score. The nutritional assessment was evaluated by subjective global assessment (SGA), anthropometry, handgrip strength, Mendenhall score, and a new malnutrition score
(defined by alteration in any nutritional parameter). The anormality of all parameters was considered when the adequation percentage was under 90%. Fifty-three percent of
patients were male, 43% had liver cirrhosis, 80% had viral etiology, with a mean age of 54 12 years. There was a significative relationship between the severity of liver dysfunction and SGA, Mendenhall score, and the new malnutrition score. The isolated assessment of anthropometry had no relationship with the severity of liver dysfunction.
According to SGA, the prevalence of malnutrition was 10% for non-cirrhotic hepatic disease, 16% for compensated cirrhosis, and 94% for descompensated cirrhosis. According to Mendenhall score, the rates were 31%, 38%, and 56%, respectively.
According to the new malnutrition score, the rates were 52%, 60%, and 96%, respectively. Although there had had a significant reduction in handgrip strength with the severity of malnutrition, we cant establish a cut-off value. The performance of handgrip strength adequation percentage as a criteria for diagnosing malnutrition showed 56% of false-positive and 24% of false-negative results. The prevalence of malnutrition is variable in patients with chronic liver diseases. It depends on the method used to evaluate nutritional status and the severity of liver dysfunction. Not surprisingly, the scores who combined multiple parameters of nutritional assessment showed the higher prevalence of malnutrition. There was a significant association between nutritional status and severity of liver dysfunction. If we add the measurement of handgrip strength to nutritional assessment, the prevalence rates of malnutrition will increase because of false-positive results.
|
7 |
Osteoporosis in chronic liver diseaseOrmarsdóttir, Sif January 2001 (has links)
<p>Ormarsdóttir, S. 2001. Osteoporosis in Chronic Liver Disease. Acta Universitatis Upsaliensis. <i>Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine</i> 1037. 60 pp. Uppsala. ISBN 91-554-5021-0. </p><p>Osteoporosis is a well-known and frequently reported complication of chronic liver disease (CLD) with a high fracture rate contributing to significant morbidity after liver transplantation. The pathogenesis is unknown and controversy exists about many risk factors for osteoporosis in CLD. </p><p>In the present thesis, bone mineral density (BMD) was found to be significantly lower at the lumbar spine (<i>p</i><0.01) in a cohort of patients with CLD compared with age- and gender -matched individuals. Osteoporosis was found in 30% of the patients and 15% of the controls, respectively. Low body mass index (BMI), corticosteroid treatment, prothrombin time, age and female gender were independent risk factors for osteoporosis in the patients. </p><p>In a follow-up study, 43 of 72 patients were available for a second BMD measurement 25 months (median) after the first. Bone loss at the femoral neck was 1.5 ± 2.4% in females and 2.9 ± 2.0% in males with a significant decrease in BMD Z-score over time (<i>p</i>=0.005 and <i>p</i>=0.02 for females and males, respectively), indicating increased bone loss at this site. Hyperbilirubinaemia and low circulating levels of 25-hydroxy vitamin D<sub>3</sub> predicted increased bone loss at the femoral neck. These findings suggest that cortical bone, in addition to trabecular bone, may be affected in CLD and bilirubin and vitamin D<sub>3</sub> may be involved in the pathophysiology of osteoporosis in CLD. </p><p>In order to elucidate the suggested role of insulin-like growth factors (IGFs) and leptin in the pathophysiology of osteoporosis in CLD, we studied the relationship between these factors and BMD. Levels of IGFs were extremely low (<i>p</i><0.0001 compared with the controls) and related to liver function but no correlation was found between the IGFs and BMD. Serum leptin adjusted for BMI correlated negatively with BMD in female patients (<i>p</i>=0.003 and <i>p</i>=0.04 at the lumbar spine and the femoral neck, respectively) and in male patients at the femoral neck (<i>p</i>=0.04). Thus, the IGFs appear not to be involved in the pathophysiology of osteoporosis in CLD but a role of circulating leptin is possible. </p>
|
8 |
Osteoporosis in chronic liver diseaseOrmarsdóttir, Sif January 2001 (has links)
Ormarsdóttir, S. 2001. Osteoporosis in Chronic Liver Disease. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1037. 60 pp. Uppsala. ISBN 91-554-5021-0. Osteoporosis is a well-known and frequently reported complication of chronic liver disease (CLD) with a high fracture rate contributing to significant morbidity after liver transplantation. The pathogenesis is unknown and controversy exists about many risk factors for osteoporosis in CLD. In the present thesis, bone mineral density (BMD) was found to be significantly lower at the lumbar spine (p<0.01) in a cohort of patients with CLD compared with age- and gender -matched individuals. Osteoporosis was found in 30% of the patients and 15% of the controls, respectively. Low body mass index (BMI), corticosteroid treatment, prothrombin time, age and female gender were independent risk factors for osteoporosis in the patients. In a follow-up study, 43 of 72 patients were available for a second BMD measurement 25 months (median) after the first. Bone loss at the femoral neck was 1.5 ± 2.4% in females and 2.9 ± 2.0% in males with a significant decrease in BMD Z-score over time (p=0.005 and p=0.02 for females and males, respectively), indicating increased bone loss at this site. Hyperbilirubinaemia and low circulating levels of 25-hydroxy vitamin D3 predicted increased bone loss at the femoral neck. These findings suggest that cortical bone, in addition to trabecular bone, may be affected in CLD and bilirubin and vitamin D3 may be involved in the pathophysiology of osteoporosis in CLD. In order to elucidate the suggested role of insulin-like growth factors (IGFs) and leptin in the pathophysiology of osteoporosis in CLD, we studied the relationship between these factors and BMD. Levels of IGFs were extremely low (p<0.0001 compared with the controls) and related to liver function but no correlation was found between the IGFs and BMD. Serum leptin adjusted for BMI correlated negatively with BMD in female patients (p=0.003 and p=0.04 at the lumbar spine and the femoral neck, respectively) and in male patients at the femoral neck (p=0.04). Thus, the IGFs appear not to be involved in the pathophysiology of osteoporosis in CLD but a role of circulating leptin is possible.
|
9 |
Resposta de crianças portadoras de síndrome de Down e de hepatopatia crônica a uma vacina inativada (HAVRIX) contra hepatite AFerreira, Cristina Helena Targa January 2001 (has links)
Objetivo: A vacina inativada contra HVA (Havrix) é altamente eficaz e segura em crianças saudáveis. Não há muitos dados disponíveis na literatura sobre a resposta de crianças imunocomprometidas à essa vacina. O objetivo deste estudo foi avaliar a resposta de pacientes pediátricos portadores de Síndrome de Down e de Hepatopatia Crônica à uma vacina inativada contra Hepatite A, comparando suas respostas com as de crianças saudáveis. Casuística e Métodos: Foi realizado um estudo prospectivo, aberto e controlado com 138 crianças e adolescentes, de 1 a 16 anos, suscetíveis à infecção pelo virus A (anti-HVA negativo). Os indivíduos foram divididos em 3 grupos: Grupo I: portadores de Síndrome de Down (n = 49), Grupo II: Hepatopatas Crônicos (n = 34) e Grupo III: controle, composto por crianças saudáveis (n = 55). Todos os indivíduos recebiam 2 doses, nos meses 0 e 6, da vacina Havrix 720 UE , aplicada intramuscular, no deltóide. Um mês após cada dose da vacina, as crianças e os adolescentes eram submetidas à coleta de sangue para realização de titulação de anticorpos anti-HVA. Resultados: As taxas de soroconversão, após a primeira dose da vacina, no mês 1, foram de 92%, 76% e 94% nos grupos I, II e III, respectivamente. Um mês após a segunda dose, as porcentagens de soroconversão foram de 100% x 97% x 100%, para os grupos, na mesma ordem. As médias geométricas dos títulos de anticorpos anti-HVA foram, na primeira e segunda coletas, de 164,02 e 1719,86 mUI/ml nas crianças com Síndrome de Down, de 107,77 e 812,40 mUI/ml nos cirróticos e de 160,77 e 2344,90 mUI/ml, no grupo controle. O grupo dos pacientes cirróticos apresentou diferença estatisticamente significativa em relação às taxas de soroconversão no primeiro mês, após 1 dose da vacina, e aos títulos de anticorpos anti-HVA no final do estudo, quando comparado aos controles saudáveis. Apenas 14% dos indivíduos vacinados apresentaram sintomas locais, como dor e vermelhidão. Cinco porcento apresentaram sintomas gerais. Não ocorreu nenhum efeito adverso sério ou reação imediata à vacina. Os efeitos adversos diminuíram por ocasião da segunda dose.Conclusões: A vacina inativada Havrix, contra Hepatite A, provoca altas taxas de soroconversão e é altamente segura em pacientes pediátricos portadores de Síndrome de Down e de Cirrose. As crianças e adolescentes com Cirrose respondem à vacina inativada anti-HVA com títulos de anticorpos mais baixos do que as crianças saudáveis e do que as portadoras de Síndrome de Down. / Objective: The inactivated hepatitis A vaccine (Havrix) is highly immunogenic and safe in healthy children. However, data about the response of immunocompromised children to this vaccine are not very frequent in the literature. The objective of this study was to assess the response of pediatric patients with Down syndrome and chronic liver disease to an inactivated hepatitis A vaccine, and to compare their responses to those of healthy children. Patients and Methods: A prospective, open-label, controlled study was performed with 138 children and adolescents susceptible to hepatitis A virus (anti-HAV negative) with ages between 1 and 16 years. Patients were divided into three groups: Group I, Down syndrome patients (n = 49); Group II, patients with chronic liver disease (n = 34); and Group III, healthy children/controls (n = 55). All patients and controls received two intramuscular doses of Havrix 720 UE in the deltoid muscle at months 0 and 6. One month after each dose, patients underwent blood collection for the assessment of anti-HAV titers. Results: Seroconversion rates after the first dose (month 1) were 92%, 76%, and 94% in Groups I, II, and III, respectively; one month after the second dose, these percentages were 100%, 97%, and 100%. Geometric mean titers were 164.02 and 1719.86 mUI/ml in the first and second collections for Down syndrome children; 107.77 and 812.40 mUI/ml for cirrhotic patients; and 160.77 and 2344.90 mUI/ml for controls. The group of cirrhotic patients presented a statistically significant difference in seroconversion rates at month 1, and in anti-HAV titers in the end of the study when compared to healthy controls. Only 14% of the vaccinated individuals presented local symptoms, such as pain and redness; 5% presented general symptoms. No severe adverse effects or immediate reaction to the vaccine were observed. The occurrence of adverse reactions was lower in the application of the second dose. Conclusions: The inactivated hepatitis A vaccine (Havrix) presents high rates of seroconversion and is highly safe in pediatric patients with Down syndrome and cirrhosis. Cirrhotic children and adolescents have responded to the inactivated hepatitis A vaccine with lower antibody titers when compared to healthy children and Down syndrome.
|
10 |
Questionário para Avaliação de Qualidade de Vida em Portadores de Doença Hepática Crônica: Tradução e Validação do CLDQ – Chronic Liver Disease Questionnaire / Questionnaire for health related quality of life avaliation em patients with chronic liver disease: Translation and validation of CLDQ – Chronic Liver Disease QuestionnaireMucci, Samantha [UNIFESP] 29 April 2009 (has links) (PDF)
Made available in DSpace on 2015-07-22T20:50:41Z (GMT). No. of bitstreams: 0
Previous issue date: 2009-04-29 / Nesse estudo objetivou-se realizar a tradução para o português e a adaptação cultural do instrumento Chronic Liver Disease Questionnaire (CLDQ) para uso no Brasil. O instrumento foi traduzido da versão original (Inglês) para a língua portuguesa pelos autores e, posteriormente, revisado e avaliado quanto ao grau de dificuldade das traduções e equivalência por tradutores bilíngües. O instrumento foi, então, aplicado em 20 pacientes com hepatopatia crônica selecionados aleatoriamente. Não houve dificuldade na compreensão do instrumento, todas as questões foram consideradas aplicáveis pelos pacientes, e a equivalência cultural do CLDQ foi demonstrada sem que mudanças na tradução original precisassem ser feitas. A tradução e a adaptação cultural do CLDQ para o português, no Brasil, foram realizadas, tendo sido cumprida esta importante etapa para sua validação e utilização em nosso meio. / The aim of this study was to carry out the translation from English into Portuguese and the transcultural adaptation of the Chronic Liver Disease Questionnaire to use in Brazil. The instrument was translated from the original version (English) into Portuguese language by the authors and then, it was revised. The degree of difficulty of the translations and equivalence for bilingual translators were evaluated. The instrument was, then, applied in 20 patients with chronic liver disease randomly selected. It was easy to the patients understand the instrument, all the questions had been considered applicable by the patients, and the cultural equivalence of the CLDQ was demonstrated without changes in the original translation. The translation and the transcultural adaptation of CLDQ into Portuguese, in Brazil, had been carried out, having been fulfilled to this important stage for its validation and use in our way. / TEDE / BV UNIFESP: Teses e dissertações
|
Page generated in 0.109 seconds